MMH-450

MMH-450 is an investigational drug candidate developed by Materia Medica Holding, a pharmaceutical company based in Russia. It is primarily being developed for the treatment of sleep disorders, including insomnia. The drug is currently in early-stage clinical development, with a Phase 1, open-label, non-randomized trial (NCT05443425) initiated to evaluate its safety and tolerability in healthy volunteers. MMH-450 likely utilizes the company's proprietary "release-active" technology, which involves the use of highly diluted, technologically processed antibodies to modulate the activity of specific biological targets, such as neurotransmitter receptors involved in the regulation of the sleep-wake cycle.